カテゴリ： GlobalData, アメリカ, 企業調査

Dynavax Technologies Corp (DVAX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Dynavax Technologies Corp (DVAX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10124
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：58
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Dynavax Technologies Corp (Dynavax), formerly Double Helix Corp, is a clinical-stage biopharmaceutical company that develops product candidates for the prevention of infectious and inflammatory disease. The company’s only marketed product Heplisav-B is an adult vaccine for hepatitis B. Its pipeline includes AZD1419, a drug for the treatment of asthma; DV281, an agonist which focuses on lung tumors and lung metastases; and SD-101, an agonist focusing on immune response to various cancers. Dynavax’s pre-clinical pipeline encompasses DV230F for liver tumors, DV1001 for multiple malignancies. The company develops immunotherapies based on toll-like receptor technology for the treatment and prevention of infectious and inflammatory diseases and cancer. It has subsidiary in Germany. Dynavax is headquartered in Berkeley, California, the US.

Dynavax Technologies Corp (DVAX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dynavax Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dynavax Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Dynavax Raises USD40 Million from Hercules Technology 12
Double Helix Raises USD0.048 Million in Seed Financing 13
Partnerships 14
Dynavax Technologies and Quantum Leap Healthcare Collaborative Enter into Agreement 14
Vectura Enters into Agreement with Dynavax Technologies 15
Blirt Enters into Agreement with Rhein Biotech for Cancer Vaccine 16
Equity Offering 17
Dynavax Technologies Plans to Raise USD150 Million in Public Offering of Shares 17
Dynavax Technologies Raises USD86.2 Million in Public Offering of Shares 18
Dynavax Technologies Raises USD143.8 Million in Public Offering of Shares 20
Dynavax Technologies Completes Public Offering Of Shares For US$85.5 Million 22
Dynavax Technologies Completes Public Offering Of Preferred Stock For US$46.7 Million 23
Dynavax Technologies Announces Public Offering Of Shares For US$50 Million 24
Dynavax Technologies Completes Public Offering Of Common Stock For US$74 Million 25
Debt Offering 26
Dynavax Technologies to Raise USD100 Million in Private Placement of Notes 26
Acquisition 27
McCann Health Acquires Double Helix, Provider Of Healthcare Consultancy Services, For US$78 Million 27
Dynavax Technologies Corp – Key Competitors 28
Dynavax Technologies Corp – Key Employees 29
Dynavax Technologies Corp – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 05, 2018: Dynavax reports third quarter 2018 financial results, progress on HEPLISAV-B launch, and updated SD-101 data in three patient populations 31
Aug 06, 2018: Dynavax reports second quarter 2018 financial results 33
May 08, 2018: Dynavax Announces First Quarter 2018 Financial Results 34
Mar 08, 2018: Dynavax Reports Fourth Quarter and Year End 2017 Financial Results 35
Nov 03, 2017: Dynavax Reports Third Quarter 2017 Financial Results 36
Aug 02, 2017: Dynavax Reports Second Quarter 2017 Financial Results 37
May 08, 2017: Dynavax Reports First Quarter 2017 Financial Results 38
Mar 13, 2017: Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update 39
Corporate Communications 41
Jun 28, 2018: Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs 41
Mar 02, 2018: Stanley A. Plotkin, M.D. Steps Down from Board of Dynavax Technologies 43
Product News 44
06/02/2017: Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy 44
05/19/2017: Dynavax to Present Data on SD-101 in Combination with KEYTRUDA at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 45
05/16/2018: Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting 46
04/17/2018: Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting 47
04/16/2018: Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck 48
03/20/2017: Dynavax to Present Data on SD-101 at the 2017 American Association for Cancer Research Annual Meeting 50
03/20/2017: Dynavax to Present Data on TLR9-Adjuvanted Nanoparticle Cancer Vaccine at the 2017 American Association for Cancer Research Annual Meeting 51
03/20/2017: Dynavax to Present DV-281 at the 2017 American Association for Cancer Research Annual Meeting 52
03/15/2018: Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA for Presentation at the 2018 American Association for Cancer Research Annual Meeting 53
03/06/2017: Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies 54
01/05/2017: Dynavax Provides Update on SD-101 Oncology Program 55
Clinical Trials 56
Oct 19, 2017: Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy 56
Jan 05, 2017: Dynavax Provides Update on DV-281 Oncology Program 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dynavax Technologies Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dynavax Technologies Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Dynavax Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dynavax Raises USD40 Million from Hercules Technology 12
Double Helix Raises USD0.048 Million in Seed Financing 13
Dynavax Technologies and Quantum Leap Healthcare Collaborative Enter into Agreement 14
Vectura Enters into Agreement with Dynavax Technologies 15
Blirt Enters into Agreement with Rhein Biotech for Cancer Vaccine 16
Dynavax Technologies Plans to Raise USD150 Million in Public Offering of Shares 17
Dynavax Technologies Raises USD86.2 Million in Public Offering of Shares 18
Dynavax Technologies Raises USD143.8 Million in Public Offering of Shares 20
Dynavax Technologies Completes Public Offering Of Shares For US$85.5 Million 22
Dynavax Technologies Completes Public Offering Of Preferred Stock For US$46.7 Million 23
Dynavax Technologies Announces Public Offering Of Shares For US$50 Million 24
Dynavax Technologies Completes Public Offering Of Common Stock For US$74 Million 25
Dynavax Technologies to Raise USD100 Million in Private Placement of Notes 26
McCann Health Acquires Double Helix, Provider Of Healthcare Consultancy Services, For US$78 Million 27
Dynavax Technologies Corp, Key Competitors 28
Dynavax Technologies Corp, Key Employees 29
Dynavax Technologies Corp, Subsidiaries 30

List of Figures
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dynavax Technologies Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Dynavax Technologies Corp (DVAX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • 21st Century Oncology Inc：企業の戦略的SWOT分析
    21st Century Oncology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Ibersol S.G.P.S., S.A.：企業の戦略・SWOT・財務分析
    Ibersol S.G.P.S., S.A. - Strategy, SWOT and Corporate Finance Report Summary Ibersol S.G.P.S., S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • NightstaRx Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary NightstaRx Ltd (NightstaRx) a subsidiary of Nightstar Therapeutics PLC is a clinical-stage gene therapy company that engaged in developing and commercializing novel. The company also involved in providing one-time treatments for patients suffering from rare inherited retinal diseases. It pro …
  • Siam Food Products PCL：企業の戦略・SWOT・財務情報
    Siam Food Products PCL - Strategy, SWOT and Corporate Finance Report Summary Siam Food Products PCL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • DURECT Corp (DRRX)-医療機器分野：企業M&A・提携分析
    Summary DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s …
  • American Axle & Manufacturing Holdings Inc (AXL)：企業の財務・戦略的SWOT分析
    American Axle & Manufacturing Holdings Inc (AXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Kellwood Company, LLC：企業の戦略・SWOT・財務情報
    Kellwood Company, LLC - Strategy, SWOT and Corporate Finance Report Summary Kellwood Company, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Eu Yan Sang International Ltd：企業の戦略的SWOT分析
    Eu Yan Sang International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Humabs BioMed SA-製薬・医療分野：企業M&A・提携分析
    Summary Humabs BioMed SA (Humabs) is an antibody therapeutics biotechnology company that discovers and develops human monoclonal antibodies. The company’s pipeline programs include Flu A virus, ebola virus, HBV, rabies virus, JCV, dengue, and others. It develops cellclone technologies, a proprietary …
  • Kongsberg Maritime AS：企業の戦略的SWOT分析
    Kongsberg Maritime AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • The Wendy’s Company：企業の戦略・SWOT・財務情報
    The Wendy’s Company - Strategy, SWOT and Corporate Finance Report Summary The Wendy’s Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Leaf Clean Energy Company (LEAF)：企業の財務・戦略的SWOT分析
    Summary Leaf Clean Energy Company (Leaf Clean Energy) is a provider of renewable energy and sustainable technology investments. It offers growth and venture capital across the renewable energy industry to support novelty, well-managed and rapidly-growing companies. It operates and manages energy pro …
  • Centene Corp (CNC)：製薬・医療：M&Aディール及び事業提携情報
    Summary Centene Corp (Centene) is a healthcare service provider that offers services to government sponsored healthcare programs with focus on under-insured and uninsured individuals. It provides health plans through Medicaid, Medicare and Health Insurance Marketplace contracts; and other health sol …
  • Etex Group Sa
    Etex Group Sa - Strategy, SWOT and Corporate Finance Report Summary Etex Group Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • ActiveCare Inc (ACAR)：企業の財務・戦略的SWOT分析
    Summary ActiveCare Inc (ActiveCare) is a medical equipment company that monitors health analytics. The company provides monitoring component to traditional disease management and wellness solutions. It offers solutions such as diabetes supplies, online web-based administrative tools, browser and iPh …
  • Stantec Inc (STN)：電力：M&Aディール及び事業提携情報
    Summary Stantec Inc. (Stantec) is a construction and consulting services company. The company offers architectural, engineering, and environmental services. Its service portfolio includes architecture and interior design, building engineering, community design services, geomatics, geotechnical engin …
  • QinetiQ Group plc：企業のM&A・事業提携・投資動向
    QinetiQ Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's QinetiQ Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Respira Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Respira Therapeutics Inc (Respira) is a pharmaceutical development company that develops dry powder inhaler technologies. The company develops Inhaler technologies to enable targeted lung delivery of drugs to treat pulmonary diseases. It develops products used for the treatment of pulmonary …
  • Metabolomic Diagnostics Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Metabolomic Diagnostics Ltd (Metabolomic Diagnostics) is an early stage medical diagnostic company that develops technology to provide predictive diagnosis of pre-eclampsia in early pregnancy. The company uses metabolic profiling for investigating the low molecular weight biochemicals existi …
  • AutoNation, Inc.：企業の戦略・SWOT・財務情報
    AutoNation, Inc. - Strategy, SWOT and Corporate Finance Report Summary AutoNation, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆